Sarcoidosis: Oral Sirolimus for Facial Skin Involvement

We are studying whether sirolimus can improve facial skin symptoms in patients with sarcoidosis. The trial also examines its effects on quality of life and overall skin health.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Sirolimus
Sirolimus is a substance that suppresses the immune system to help prevent rejection after organ transplantation.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Assistance Publique Hopitaux De Paris
Dermatologie et allergologie
Bagnolet, France
Assistance Publique Hopitaux De Paris
Service de Dermatologie
Créteil, France
Assistance Publique Hopitaux De Paris
Service de Dermatologie
Quinze-Vingts, France

Sponsor: Assistance Publique Hopitaux De Paris
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.